SIGA TECHNOLOGIES INC (SIGA) competitors & alternatives
Health Care · NASDAQ
SIGA TECHNOLOGIES INC (SIGA)'s top competitors and alternatives — its most similar public companies — include EMERGENT BIOSOLUTIONS INC (EBS), DISTRIBUTION SOLUTIONS GROUP INC (DSGR), BIOCRYST PHARMACEUTICALS INC (BCRX), ATEA PHARMACEUTICALS INC (AVIR), TRAVERE THERAPEUTICS INC (TVTX), Pfizer (PFE), ROCKET PHARMACEUTICALS INC (RCKT), WAVE LIFE SCIENCES LTD (WVE), BridgeBio Pharma, Inc. (BBIO), ETON PHARMACEUTCIALS INC (ETON), LARIMAR THERAPEUTICS INC (LRMR) and ACADIA PHARMACEUTICALS INC (ACAD). These are SIGA TECHNOLOGIES INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top SIGA competitors & alternatives
-
EMERGENT BIOSOLUTIONS INCEBSHealth Care
Emergent BioSolutions is a specialized biopharmaceutical firm that provides critical medical countermeasures and manufacturing services to protect against…
$7.58 (as of 2026-07-22) · market cap $393M
-
DISTRIBUTION SOLUTIONS GROUP INCDSGRIndustrials
Distribution Solutions Group is a specialty distributor of MRO (maintenance, repair, and operations) products and value-added industrial services.
$34.51 (as of 2026-07-22) · market cap $1.5B
-
BIOCRYST PHARMACEUTICALS INCBCRXHealth Care
BioCryst Pharmaceuticals is a biotech company focused on commercializing and developing innovative therapies for hereditary angioedema and other rare diseases…
$9.51 (as of 2026-07-22) · market cap $2.4B
-
ATEA PHARMACEUTICALS INCAVIRHealth Care
A clinical-stage antiviral company advancing pan-genotypic HCV and HEV therapies toward FDA submissions, leveraging proprietary nucleoside/nucleotide chemistry…
$4.81 (as of 2026-07-22) · market cap $385M
-
TRAVERE THERAPEUTICS INCTVTXHealth Care
Rare kidney disease specialist with two approved FILSPARI formulations (IgAN, FSGS) and a clinical-stage enzyme therapy poised to become the first…
$56.26 (as of 2026-07-22) · market cap $5.2B
-
PfizerPFEHealth Care
Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular,…
$24.82 (as of 2026-07-22) · market cap $142.0B
-
ROCKET PHARMACEUTICALS INCRCKTHealth Care
Rocket Pharmaceuticals is a clinical-stage biotechnology company developing transformative gene therapies for rare, high-unmet-need genetic disorders.
$3.30 (as of 2026-07-22) · market cap $368M
-
WAVE LIFE SCIENCES LTDWVEHealth Care
A clinical-stage biotechnology company developing a versatile, multimodal RNA medicine platform to treat rare and common diseases without the need for complex…
$5.74 (as of 2026-07-22) · market cap $1.1B
-
BridgeBio Pharma, Inc.BBIOHealth Care
BridgeBio translates genetic science into medicines for rare genetic diseases through a decentralized portfolio model, with an FDA-approved lead product in…
$82.66 (as of 2026-07-22) · market cap $16.2B
-
ETON PHARMACEUTCIALS INCETONHealth Care
Eton Pharmaceuticals develops and commercializes rare disease treatments, with a portfolio of ten marketed products and four late-stage candidates targeting…
$43.58 (as of 2026-07-22) · market cap $1.2B
-
LARIMAR THERAPEUTICS INCLRMRHealth Care
Larimar Therapeutics is developing a novel cell-penetrating peptide platform to treat rare, genetically driven diseases, with a lead program targeting the…
$4.02 (as of 2026-07-22) · market cap $418M
-
ACADIA PHARMACEUTICALS INCACADHealth Care
Acadia Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for CNS disorders and rare…
$24.96 (as of 2026-07-22) · market cap $4.4B
Not quite? Describe exactly what you want →
Peers are SIGA TECHNOLOGIES INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: SIGA TECHNOLOGIES INC (SIGA).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.